US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Odyssey Therapeutics, Inc.(ODTX): IPO Breaks Issue After Aggressive Upsizing

Odyssey Therapeutics, Inc.(ODTX): Biotech Combating Ulcerative Colitis, or UC, Files for IPO

Odyssey Therapeutics, Inc.(ODTX): Ulcerative Colitis Revives IPO Plans, Sets Terms

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

IPOs and Secondary Offerings

Equity Capital Markets

Odyssey Therapeutics / Equity Capital Markets

<ul>
<li>Lead asset OD-001 shows Phase 2a proof-of-concept in ulcerative colitis, providing a relatively advanced pipeline versus typical biotech IPOs.</li>
<li>Backing from top-tier investors and a $25M concurrent private placement reinforces confidence and supports aftermarket stability.</li>
<li>Risk-Reward skews positive despite prior IPO delay, supported by strong demand, credible leadership, and improving biotech market conditions.</li>
</ul>


Lead asset OD-001 shows Phase 2a proof-of-concept in ulcerative colitis, providing a relatively advanced pipeline versus typical biotech IPOs.
Backing from top-tier investors and a $25M concurrent private placement reinforces confidence and supports aftermarket stability.
Risk-Reward skews positive despite prior IPO delay, supported by strong demand, credible leadership, and improving biotech market conditions.


Odyssey Therapeutics, Inc.(ODTX): Solid Demand Meets Advanced Immunology Pipeline